Warning letter
Pfizer, Inc. [ARCHIVED]: warning letter of May 26, 2010
FDA warning letter 79704 · New York District Office
Key facts
| Reference number | 79704 |
|---|---|
| Company | Pfizer, Inc. [ARCHIVED] |
| Subject | Postmarketing Adverse Drug Experience Reporting Requirements |
| Issue date | May 26, 2010 |
| Posted date | May 26, 2010 |
| Issuing office | New York District Office |
| Product type | Drugs |
| CFR sections cited | 314.81, 203.31, 314.80, 203.37(a)(1), 203.37(a)(2), 203.31(d), 203.37(a)(3), 314.80(c)(1)(ii), 314.80(b), 314.80(c), 314.80(c)(1), 314.80(c)(2) and 1 more |
| Inspection city | New York |
| Inspection ZIP | 10017 |
| Inspection start date | Jun 29, 2009 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: